Sildenafil
Product Images NDC 68071-2566

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 68071-2566). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2566 3)

The text describes a medication called Sildenafil 20mg produced by uCare Pharmaceuticals, Inc. The medication comes in a bottle with 30 round, white to off-white tablets, each containing Sildenafil Citrate. The tablets are film-coated and are marked with '95' on one side and '- 3 1 5' on the other. The medication is sold under the Product# P2215030 and has an expiry date of 00-00. It comes with a warning to keep out of reach of children and to store at a controlled temperature of 68-77°F.*

FDA Label Image

Figure1 (Figure1)

FDA Label Image

Figure2 (Figure2)

This is a table of drug interactions with sildenafil. It provides recommendations for changes in dosing of different drugs based on their interaction with sildenafil. The table includes Atorvastatin, Azithromycin, Bosentan, Cimetidine, Erythromycin, and Saquinavir among others. Some drugs require no dose adjustment, while others may require co-administration. The table also shows the fold change relative to Sildenafil alone and the vertical solid line is a reference for the change in the ratio of drugs with or without Sildenafil.*

FDA Label Image

Figure3 (Figure3)

This appears to be a table of drugs that interact with Acenocoumarol along with their recommended dose adjustments. It also includes information on the effect of the drugs on INR AUC and BT as well as fold change and 90% CI recommendations. Some interactions do not require dose adjustments, while others are not recommended to be coadministered. Ritonavir's effect on Sildenafil PK is also noted.*

FDA Label Image

Figure4 (Figure4)

FDA Label Image

Figure5 (Figure5)

FDA Label Image

Figure6 (Figure6)

FDA Label Image

Figure7 (Figure7)

FDA Label Image

Structure (Structure)

FDA Label Image

Camber1 (Camber1)

FDA Label Image

Camber2 (Camber2)

FDA Label Image

Image1 (Image1)

The text describes a graph presenting the mean change from baseline (in meters) for different treatments at different time intervals up to week 12. The treatments mentioned are B—a—a EHildenaflil 1mg TID, Sildenafil Smg TID, and Eildenalil 20mg TID. However, no concrete information about what these treatments are for is provided.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.